Christof Vulsteke discusses KEYNOTE-905 results with Ashish Kamat. The phase 3 trial enrolled cisplatin-ineligible muscle-invasive bladder cancer patients, median age 73, receiving perioperative ...

Evidence of metastatic disease on PSMA PET/CT. Allergy to POSLUMA or gadolinium. Inability to tolerate MRI due to claustrophobia or posture/back-hip issues.

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

Approximately three-quarters of patients newly diagnosed with bladder cancer have non-muscle-invasive disease (NMIBC). Among these patients, those with high-risk (HR) features should be managed more ...

Data from Artera’s DIRECT-AI registry will assess the test’s impact on cancer care and guide future improvements Reno, Nevada (UroToday.com) -- Artera, the developer of multimodal artificial ...

Urothelial bladder cancer constitutes one of the most common malignancies of the urinary tract, comprising 90-95% of urothelial carcinomas. Only 25% of patients present with muscle-invasive bladder ...

Login to update email address, newsletter preferences and use bookmarks.

At the 2025 UCSF-UCLA PSMA Conference, Alfred Morgenstern discusses his work with actinium-PSMA therapy for prostate cancer. He reviews clinical programs including Mike Sathekge's work with ...

At the 2025 UCSF-UCLA PSMA Conference, Matthias Eiber discusses lutetium PSMA therapy beyond six standard cycles. He distinguishes between extended treatment (continuous administration) and ...

At the 2025 UCSF-UCLA PSMA Conference, Irène Buvat discusses how AI can simplify personalized dosimetry in radiopharmaceutical therapy, addressing the "catch-22" where complexity limits clinical use ...

At the 2025 UCSF-UCLA PSMA Conference, Daniel Spratt presents on bone scan obsolescence in prostate cancer imaging. He demonstrates they fail to detect cancer with sufficient sensitivity compared to ...

At the 2025 UCSF-UCLA PSMA Conference, EmmanuelAntonarakis reviews US guidelines for PSMA-PET in prostate cancer from NCCN, SNMMI, and AUA/SUO. He notes consensus on use for biochemical recurrence and ...